CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | P450 inhibitor |
|
Accession: | CHEBI:50183
|
browse the term
|
Definition: | An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances. |
Synonyms: | related_synonym: | CYP2D6 inhibitor; CYP2D6 inhibitors; P450 inhibitors; cytochrome P450 inhibitor; cytochrome P450 inhibitors |
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
3,3'-diindolylmethane results in increased expression of ABCB1 mRNA [3,3'-diindolylmethane results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; Ketoconazole inhibits the reaction [3,3'-diindolylmethane results in increased expression of ABCB1 mRNA] |
CTD |
PMID:25542144 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Actg1 |
actin, gamma 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in decreased expression of ACTG1 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232 Ensembl chr 3:105,619,737...105,624,232
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of ADGRE1 mRNA] |
CTD |
PMID:24162184 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects response to substance affects localization multiple interactions |
ISO EXP |
AHR protein affects the susceptibility to 3,3'-diindolylmethane 3,3'-diindolylmethane affects the localization of AHR protein 3,3'-diindolylmethane binds to and results in decreased activity of AHR protein; 3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] 3,3'-diindolylmethane binds to and results in increased activity of AHR protein; 3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] 3,3'-diindolylmethane binds to and results in increased activity of AHR protein; 3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; 3,3'-diindolylmethane promotes the reaction [AHR protein binds to CYP1A1 promoter]; AHR mutant form inhibits the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]; AHR mutant form inhibits the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]] |
CTD |
PMID:8384853 PMID:9771935 PMID:11294972 PMID:16972788 PMID:19056653 PMID:19223575 PMID:20435555 PMID:23583297 More...
|
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of AIF1 protein] |
CTD |
PMID:24162184 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Ar |
androgen receptor |
decreases activity |
ISO |
3,3'-diindolylmethane results in decreased activity of AR protein |
CTD |
PMID:30247711 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [ARNT protein binds to CYP1A1 promoter] |
CTD |
PMID:16972788 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of ATF3 |
CTD |
PMID:15670751 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of ATP5F1A mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases phosphorylation |
ISO |
3,3'-diindolylmethane results in decreased phosphorylation of BAD protein |
CTD |
PMID:22290291 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of BAX protein |
CTD |
PMID:22290291 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 |
CTD |
PMID:22290291 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein] 3,3'-diindolylmethane analog results in decreased expression of BCL2 mRNA 3,3'-diindolylmethane analog results in decreased expression of BCL2 protein; 3,3'-diindolylmethane results in decreased expression of BCL2 protein |
CTD |
PMID:16051428 PMID:16580691 PMID:22290291 PMID:26593444 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of BCL2L1 mRNA; 3,3'-diindolylmethane results in increased expression of BCL2L1 protein |
CTD |
PMID:18025290 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of BCL2L10 mRNA |
CTD |
PMID:22514694 |
|
NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of BIRC5 protein |
CTD |
PMID:22290291 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brd2 |
bromodomain containing 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of BRD2 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr20:4,727,078...4,735,389
Ensembl chr20:4,728,151...4,735,388
|
|
G |
Calm2 |
calmodulin 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in decreased expression of CALM2 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
3,3'-diindolylmethane results in increased activity of CASP3 protein |
CTD |
PMID:21820497 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccn1 |
cellular communication network factor 1 |
affects methylation |
ISO |
3,3'-diindolylmethane affects the methylation of CCN1 promoter |
CTD |
PMID:24466240 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CCNB1 |
CTD |
PMID:22290291 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
3,3'-diindolylmethane analog results in decreased expression of CCND1 protein; 3,3'-diindolylmethane results in decreased expression of CCND1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [3,3'-diindolylmethane analog results in decreased expression of CCND1 protein] |
CTD |
PMID:16051428 PMID:22290291 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CCND3 protein |
CTD |
PMID:22514694 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
affects methylation |
ISO |
3,3'-diindolylmethane affects the methylation of CCR4 promoter |
CTD |
PMID:24466240 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Cd40lg |
CD40 ligand |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of CD40LG mRNA |
CTD |
PMID:22514694 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of CD69 protein] |
CTD |
PMID:24200994 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CDC25C |
CTD |
PMID:22290291 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in decreased expression of CDH1 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of CDH1 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in decreased expression of CDH1 protein] |
CTD |
PMID:28844962 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CDH11 protein |
CTD |
PMID:18025290 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of CDH2 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of CDH2 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of CDH2 protein] |
CTD |
PMID:28844962 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO |
3,3'-diindolylmethane promotes the reaction [CDK2 protein binds to CDKN1A protein] 3,3'-diindolylmethane results in decreased activity of CDK2 protein |
CTD |
PMID:15611077 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CDK4 protein |
CTD |
PMID:22514694 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of CDK6 protein |
CTD |
PMID:22290291 PMID:22514694 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
3,3'-diindolylmethane promotes the reaction [CDK2 protein binds to CDKN1A protein] 3,3'-diindolylmethane results in increased expression of CDKN1A mRNA; 3,3'-diindolylmethane results in increased expression of CDKN1A protein |
CTD |
PMID:12203118 PMID:15611077 PMID:18025290 PMID:22290291 PMID:22495798 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of CDKN1B protein |
CTD |
PMID:22290291 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of CDKN2D protein |
CTD |
PMID:22290291 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases phosphorylation |
ISO |
3,3'-diindolylmethane results in decreased phosphorylation of CHUK protein |
CTD |
PMID:22290291 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in decreased expression of CKS1B mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of CTSB protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of CTSB protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of CTSB protein] |
CTD |
PMID:28844962 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of CTSD protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of CTSD protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of CTSD protein] |
CTD |
PMID:28844962 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
affects methylation multiple interactions |
ISO |
3,3'-diindolylmethane affects the methylation of CXCR4 promoter 3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of CXCR4 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of CXCR4 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of CXCR4 protein] |
CTD |
PMID:24466240 PMID:28844962 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
3,3'-diindolylmethane analog affects the localization of and results in increased expression of CYCS protein |
CTD |
PMID:16051428 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
ISO |
3,3'-diindolylmethane analog results in increased expression of CYP19A1 mRNA; 3,3'-diindolylmethane results in increased expression of CYP19A1 mRNA |
CTD |
PMID:11294972 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression decreases activity |
ISO EXP |
3,3'-diindolylmethane promotes the reaction [AHR protein binds to CYP1A1 promoter]; 3,3'-diindolylmethane promotes the reaction [ARNT protein binds to CYP1A1 promoter]; 3,3'-diindolylmethane promotes the reaction [ESR1 protein binds to CYP1A1 promoter]; [3,3'-diindolylmethane results in increased expression of CYP1A1 mRNA] which results in increased abundance of aflatoxin B1-DNA adduct 3,3'-diindolylmethane analog results in increased activity of CYP1A1 protein; 3,3'-diindolylmethane results in increased activity of CYP1A1 protein 3,3'-diindolylmethane results in increased expression of CYP1A1 protein 3,3'-diindolylmethane analog results in increased expression of CYP1A1 mRNA; 3,3'-diindolylmethane results in increased expression of CYP1A1 mRNA; 3,3'-diindolylmethane results in increased expression of CYP1A1 protein 3,3'-diindolylmethane results in decreased activity of CYP1A1 protein |
CTD |
PMID:8384853 PMID:9771935 PMID:11179685 PMID:11294972 PMID:11597580 PMID:15672752 PMID:16972788 PMID:19770484 PMID:22495798 PMID:23583297 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression decreases activity increases oxidation |
ISO EXP |
[3,3'-diindolylmethane results in increased expression of CYP1A2 mRNA] which results in increased abundance of aflatoxin B1-DNA adduct; Quercetin inhibits the reaction [CYP1A2 protein results in increased oxidation of 3,3'-diindolylmethane]; resveratrol inhibits the reaction [CYP1A2 protein results in increased oxidation of 3,3'-diindolylmethane] 3,3'-diindolylmethane results in increased expression of CYP1A2 protein 3,3'-diindolylmethane results in increased expression of CYP1A2 mRNA; 3,3'-diindolylmethane results in increased expression of CYP1A2 protein 3,3'-diindolylmethane results in decreased activity of CYP1A2 protein |
CTD |
PMID:8384853 PMID:15672752 PMID:16544949 PMID:19770484 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
3,3'-diindolylmethane analog results in increased expression of CYP1B1 mRNA; 3,3'-diindolylmethane results in increased expression of CYP1B1 mRNA |
CTD |
PMID:11294972 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
3,3'-diindolylmethane results in increased expression of CYP2B1 protein |
CTD |
PMID:8384853 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
3,3'-diindolylmethane results in increased expression of CYP2B2 protein |
CTD |
PMID:8384853 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression decreases activity multiple interactions |
ISO |
3,3'-diindolylmethane results in increased expression of CYP3A4 mRNA 3,3'-diindolylmethane results in decreased activity of CYP3A4 protein [3,3'-diindolylmethane results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [3,3'-diindolylmethane results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:19770484 PMID:25542144 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of DDIT3 protein |
CTD |
PMID:22290291 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of DNMT1 mRNA |
CTD |
PMID:24466240 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of DNMT3B mRNA |
CTD |
PMID:24466240 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of EEF1G mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]; 3,3'-diindolylmethane results in decreased phosphorylation of and results in decreased activity of ERBB2 protein |
CTD |
PMID:16580691 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
3,3'-diindolylmethane binds to and results in increased activity of ESR1 protein; 3,3'-diindolylmethane promotes the reaction [ESR1 protein binds to CYP1A1 promoter]; 3,3'-diindolylmethane promotes the reaction [ESR1 protein binds to TFF1 promoter]; ESR1 mutant form promotes the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of HMOX1 mRNA]] 3,3'-diindolylmethane results in decreased expression of ESR1 |
CTD |
PMID:16972788 PMID:19223575 PMID:23583297 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
3,3'-diindolylmethane promotes the reaction [ESR2 protein binds to KRT19 promoter]; 3,3'-diindolylmethane promotes the reaction [ESR2 protein binds to TMEM121B promoter]; ESR2 affects the reaction [3,3'-diindolylmethane promotes the reaction [NCOA2 protein binds to KRT19 promoter]]; ESR2 affects the reaction [3,3'-diindolylmethane results in increased expression of KRT19 mRNA]; ESR2 affects the reaction [3,3'-diindolylmethane results in increased expression of TMEM121B mRNA]; Raloxifene Hydrochloride inhibits the reaction [3,3'-diindolylmethane results in increased expression of ESR2 mRNA]; Tamoxifen inhibits the reaction [3,3'-diindolylmethane results in increased expression of ESR2 mRNA] |
CTD |
PMID:20160136 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fau |
FAU ubiquitin like and ribosomal protein S30 fusion |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in decreased expression of FAU mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of GDF15 mRNA |
CTD |
PMID:15670751 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of GNAS mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of GREB1 mRNA |
CTD |
PMID:23583297 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
ISO |
3,3'-diindolylmethane results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:22290291 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression multiple interactions |
ISO |
3,3'-diindolylmethane results in decreased expression of GSTM1 mRNA [3,3'-diindolylmethane results in decreased expression of GSTM1 mRNA] which results in increased abundance of aflatoxin B1-DNA adduct |
CTD |
PMID:19770484 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
H3f3a |
H3.3 histone A |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of H3-3A mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of HDAC1 mRNA] |
CTD |
PMID:24200994 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac10 |
histone deacetylase 10 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [enterotoxin B, staphylococcal results in decreased expression of HDAC10 mRNA] |
CTD |
PMID:24200994 |
|
NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression multiple interactions |
ISO |
3,3'-diindolylmethane results in decreased expression of HDAC2 protein 3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of HDAC2 mRNA] |
CTD |
PMID:22800507 PMID:24200994 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [enterotoxin B, staphylococcal results in decreased expression of HDAC5 mRNA] |
CTD |
PMID:24200994 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased expression of HDAC8 mRNA] |
CTD |
PMID:24200994 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of HMOX1 mRNA]; AHR mutant form inhibits the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]; ESR1 mutant form promotes the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:23583297 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of HRK mRNA |
CTD |
PMID:22514694 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression multiple interactions |
ISO |
3,3'-diindolylmethane analog results in decreased expression of HSPA5 protein 3,3'-diindolylmethane analog promotes the reaction [HSPA5 protein affects the expression of and affects the activity of MMP9 protein] |
CTD |
PMID:25794856 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of HSPB1 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IFNG protein] |
CTD |
PMID:24200994 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL2 protein] |
CTD |
PMID:24200994 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
3,3'-diindolylmethane results in increased expression of IL6 mRNA 3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of IL6 protein] |
CTD |
PMID:18025290 PMID:24200994 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
3,3'-diindolylmethane analog results in decreased expression of KDR protein |
CTD |
PMID:25794856 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Klf10 |
KLF transcription factor 10 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of KLF10 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of KLK3 mRNA |
CTD |
PMID:22495798 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT18 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt19 |
keratin 19 |
multiple interactions increases expression |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of KRT19 mRNA]; 3,3'-diindolylmethane promotes the reaction [ESR2 protein binds to KRT19 promoter]; 3,3'-diindolylmethane promotes the reaction [NCOA2 protein binds to KRT19 promoter]; ESR2 affects the reaction [3,3'-diindolylmethane promotes the reaction [NCOA2 protein binds to KRT19 promoter]]; ESR2 affects the reaction [3,3'-diindolylmethane results in increased expression of KRT19 mRNA]; NCOA2 mutant form inhibits the reaction [3,3'-diindolylmethane results in increased expression of KRT19 mRNA] |
CTD |
PMID:11179685 PMID:20160136 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Magea9 |
MAGE family member A9 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of MAGEA9 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr X:142,619,282...142,624,654
Ensembl chr X:142,619,395...142,624,653
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,3'-diindolylmethane results in decreased phosphorylation of MAPK1 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]; 3,3'-diindolylmethane results in decreased phosphorylation of and results in decreased activity of MAPK1 protein |
CTD |
PMID:16580691 PMID:22290291 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
3,3'-diindolylmethane results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,3'-diindolylmethane results in decreased phosphorylation of MAPK3 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; 3,3'-diindolylmethane results in decreased phosphorylation of and results in decreased activity of MAPK3 protein |
CTD |
PMID:16580691 PMID:22290291 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
3,3'-diindolylmethane analog results in decreased expression of MDM2 mRNA |
CTD |
PMID:26593444 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of MMP2 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of MMP2 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of MMP2 protein] |
CTD |
PMID:28844962 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
3,3'-diindolylmethane analog promotes the reaction [HSPA5 protein affects the expression of and affects the activity of MMP9 protein]; 3,3'-diindolylmethane analog results in decreased expression of and results in decreased activity of MMP9 protein; 3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of MMP9 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of MMP9 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of MMP9 protein] |
CTD |
PMID:25794856 PMID:28844962 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of COX2 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
decreases expression |
ISO |
3,3'-diindolylmethane analog results in decreased expression of MYB mRNA |
CTD |
PMID:26593444 |
|
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of MYC protein 3,3'-diindolylmethane analog results in decreased expression of MYC mRNA |
CTD |
PMID:22290291 PMID:26593444 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myl6 |
myosin light chain 6 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of MYL6 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 7:910,764...914,062
Ensembl chr 7:910,774...933,791
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [NCOA2 protein binds to KRT19 promoter]; ESR2 affects the reaction [3,3'-diindolylmethane promotes the reaction [NCOA2 protein binds to KRT19 promoter]]; NCOA2 mutant form inhibits the reaction [3,3'-diindolylmethane results in increased expression of KRT19 mRNA]; NCOA2 mutant form inhibits the reaction [3,3'-diindolylmethane results in increased expression of TMEM121B mRNA] |
CTD |
PMID:20160136 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
ISO |
3,3'-diindolylmethane results in increased expression of NFE2L2 mRNA; 3,3'-diindolylmethane results in increased expression of NFE2L2 protein sulforaphane promotes the reaction [3,3'-diindolylmethane results in increased expression of NFE2L2 mRNA]; sulforaphane promotes the reaction [3,3'-diindolylmethane results in increased expression of NFE2L2 protein] |
CTD |
PMID:23583297 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:24162184 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]; AHR mutant form inhibits the reaction [3,3'-diindolylmethane promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]] 3,3'-diindolylmethane results in increased expression of NQO1 mRNA |
CTD |
PMID:15672752 PMID:22495798 PMID:23583297 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
3,3'-diindolylmethane results in increased activity of NR1I2 protein [3,3'-diindolylmethane results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [3,3'-diindolylmethane results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25542144 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Numa1 |
nuclear mitotic apparatus protein 1 |
multiple interactions |
EXP |
3,3'-diindolylmethane inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of NUMA1 protein] |
CTD |
PMID:26251508 |
|
NCBI chr 1:156,297,907...156,372,855
Ensembl chr 1:156,326,259...156,372,855
|
|
G |
Nup133 |
nucleoporin 133 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of NUP133 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr19:51,891,606...51,941,243
Ensembl chr19:51,891,629...51,941,239
|
|
G |
Papola |
poly (A) polymerase alpha |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of PAPOLA mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[3,3'-diindolylmethane co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of PARP1 protein |
CTD |
PMID:16580691 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of PLAU mRNA |
CTD |
PMID:18025290 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of PMAIP1 |
CTD |
PMID:22290291 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
3,3'-diindolylmethane inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in decreased expression of PTEN protein] |
CTD |
PMID:26251508 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; 3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; 3,3'-diindolylmethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 protein] 3,3'-diindolylmethane inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of PTGS2 protein] 3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 3,3'-diindolylmethane results in decreased expression of PTGS2 mRNA; 3,3'-diindolylmethane results in decreased expression of PTGS2 protein |
CTD |
PMID:19056653 PMID:22290291 PMID:24162184 PMID:26251508 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression multiple interactions |
ISO EXP |
3,3'-diindolylmethane results in decreased expression of RELA protein 3,3'-diindolylmethane inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased phosphorylation of RELA protein] |
CTD |
PMID:22290291 PMID:26251508 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ribc1 |
RIB43A domain with coiled-coils 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of RIBC1 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr X:21,091,717...21,103,688
Ensembl chr X:21,091,717...21,103,200
|
|
G |
Rpl10 |
ribosomal protein L10 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of RPL10 mRNA]; 3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of RPL10 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr X:152,054,562...152,056,769
Ensembl chr X:152,054,452...152,056,761
|
|
G |
Rpl13a |
ribosomal protein L13A |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of RPL13A mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:95,609,374...95,612,557
Ensembl chr 1:95,609,370...95,620,463
|
|
G |
Rpl31 |
ribosomal protein L31 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of RPL31 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129
|
|
G |
Rpl41 |
ribosomal protein L41 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of RPL41 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 7:977,885...978,965
|
|
G |
Rpl7 |
ribosomal protein L7 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of RPL7 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 5:3,217,184...3,220,192
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of RPLP0 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rps15a |
ribosomal protein S15a |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of RPS15A mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:172,420,151...172,427,021
Ensembl chr 1:172,419,761...172,426,995
|
|
G |
Rps17 |
ribosomal protein S17 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in decreased expression of RPS17 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:135,295,920...135,298,506
Ensembl chr 1:135,295,919...135,298,535 Ensembl chr 8:135,295,919...135,298,535
|
|
G |
Rps3 |
ribosomal protein S3 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of RPS3 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
|
|
G |
Rps4x |
ribosomal protein S4, X-linked |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of RPS4X mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr X:67,298,522...67,302,965
Ensembl chr X:67,298,525...67,303,019 Ensembl chr 4:67,298,525...67,303,019
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of RPS6 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of SNAI1 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of SNAI1 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of SNAI1 protein] |
CTD |
PMID:28844962 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]; 3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]; 3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of SNAI2 protein] |
CTD |
PMID:28844962 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [ESR1 protein binds to TFF1 promoter] |
CTD |
PMID:16972788 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
affects methylation |
ISO |
3,3'-diindolylmethane affects the methylation of TGFBR1 promoter |
CTD |
PMID:24466240 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
3,3'-diindolylmethane analog results in increased expression of TIMP1 protein |
CTD |
PMID:25794856 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tmem121b |
transmembrane protein 121B |
multiple interactions increases expression |
ISO |
3,3'-diindolylmethane promotes the reaction [ESR2 protein binds to TMEM121B promoter]; ESR2 affects the reaction [3,3'-diindolylmethane results in increased expression of TMEM121B mRNA]; NCOA2 mutant form inhibits the reaction [3,3'-diindolylmethane results in increased expression of TMEM121B mRNA] |
CTD |
PMID:20160136 |
|
NCBI chr 4:153,695,191...153,700,104
Ensembl chr 4:153,698,194...153,699,912
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
3,3'-diindolylmethane results in decreased expression of TNF mRNA 3,3'-diindolylmethane inhibits the reaction [[Butylhydroxybutylnitrosamine co-treated with Cacodylic Acid] results in increased expression of TNF protein] 3,3'-diindolylmethane inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of TNF protein] |
CTD |
PMID:22514694 PMID:24200994 PMID:26251508 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:22514694 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of TNFRSF25 mRNA |
CTD |
PMID:22514694 |
|
NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
increases expression |
ISO |
3,3'-diindolylmethane results in increased expression of TNFSF8 mRNA |
CTD |
PMID:22514694 |
|
NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
3,3'-diindolylmethane results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein; [3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3; [3,3'-diindolylmethane results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of PMAIP1; wortmannin inhibits the reaction [3,3'-diindolylmethane results in increased phosphorylation of TP53 protein] |
CTD |
PMID:22290291 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf4 |
Tnf receptor associated factor 4 |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of TRAF4 mRNA |
CTD |
PMID:22514694 |
|
NCBI chr10:63,054,169...63,060,284
Ensembl chr10:63,054,181...63,060,284
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of TYMS mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ubb |
ubiquitin B |
multiple interactions |
ISO |
3,3'-diindolylmethane promotes the reaction [Estradiol results in increased expression of UBB mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
3,3'-diindolylmethane results in decreased expression of XIAP protein |
CTD |
PMID:22290291 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xrcc6 |
X-ray repair cross complementing 6 |
multiple interactions |
ISO |
3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of XRCC6 mRNA] |
CTD |
PMID:11179685 |
|
NCBI chr 7:113,542,992...113,563,762
Ensembl chr 7:113,543,057...113,563,762
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
5-hydroxymethylomeprazole results in increased expression of CYP1A1 protein |
CTD |
PMID:10103034 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 protein] |
CTD |
PMID:34599948 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein] |
CTD |
PMID:28185818 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein] |
CTD |
PMID:28185818 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] |
CTD |
PMID:28185818 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form] |
CTD |
PMID:28185818 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CD36 mRNA]; amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CD36 protein]; CD36 protein inhibits the reaction [amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]] |
CTD |
PMID:34599948 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CDKN1A protein] |
CTD |
PMID:28185818 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
amentoflavone results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression |
ISO |
amentoflavone analog results in decreased expression of DCT mRNA; amentoflavone analog results in decreased expression of DCT protein |
CTD |
PMID:17473463 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein] |
CTD |
PMID:28185818 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein] |
CTD |
PMID:28185818 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:28185818 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:28185818 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
amentoflavone results in decreased expression of NOS2 protein amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein] |
CTD |
PMID:12144868 PMID:28185818 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]; CD36 protein inhibits the reaction [amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]] |
CTD |
PMID:34599948 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects binding |
ISO |
amentoflavone binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
amentoflavone results in decreased expression of PTGS2 mRNA; amentoflavone results in decreased expression of PTGS2 protein [amentoflavone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone |
CTD |
PMID:12144868 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
amentoflavone results in decreased expression of SREBF1 mRNA |
CTD |
PMID:34599948 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:28185818 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tyr |
tyrosinase |
decreases activity |
ISO |
amentoflavone analog results in decreased activity of TYR protein |
CTD |
PMID:17473463 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
amentoflavone results in decreased activity of UGT1A1 protein |
CTD |
PMID:29470958 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity |
ISO |
amentoflavone results in decreased activity of UGT1A3 protein |
CTD |
PMID:29470958 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
decreases activity |
ISO |
amentoflavone results in decreased activity of UGT1A4 protein |
CTD |
PMID:29470958 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases activity multiple interactions |
ISO |
amentoflavone results in decreased activity of UGT1A6 protein amentoflavone inhibits the reaction [UGT1A6 protein results in increased glucuronidation of 4-cresol] |
CTD |
PMID:29470958 PMID:32421801 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases activity |
ISO |
amentoflavone results in decreased activity of UGT1A9 protein |
CTD |
PMID:29470958 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases activity |
ISO |
amentoflavone results in decreased activity of UGT2B17 protein |
CTD |
PMID:29470958 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
|
G |
Aatf |
apoptosis antagonizing transcription factor |
decreases expression |
ISO |
beauvericin results in decreased expression of AATF mRNA |
CTD |
PMID:29203277 |
|
NCBI chr10:69,299,029...69,392,207
Ensembl chr10:69,299,037...69,392,201
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ABCG1 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ACAT2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of ACIN1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ACSL4 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
beauvericin results in decreased expression of ACTB mRNA |
CTD |
PMID:29203277 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Aen |
apoptosis enhancing nuclease |
decreases expression |
ISO |
beauvericin results in decreased expression of AEN mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of AIFM1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Ak4 |
adenylate kinase 4 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of AK4 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ALDH5A1 protein |
CTD |
PMID:32407736 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
decreases expression |
ISO |
beauvericin results in decreased expression of ALDOA mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Anapc13 |
anaphase promoting complex subunit 13 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ANAPC13 protein |
CTD |
PMID:32407736 |
|
NCBI chr 8:103,205,520...103,213,936
Ensembl chr 8:103,205,520...103,213,936
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
decreases expression |
ISO |
beauvericin results in decreased expression of APRT mRNA |
CTD |
PMID:29203277 |
|
NCBI chr19:50,626,201...50,628,491
Ensembl chr19:50,626,202...50,628,431
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
beauvericin inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] |
CTD |
PMID:30716354 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
beauvericin results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:29203277 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
increases expression |
ISO |
beauvericin results in increased expression of ARPP21 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of ATP1A1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ATP1A3 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ATP5PB protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ATP5PF protein |
CTD |
PMID:32407736 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of BAX mRNA [zearalenol co-treated with beauvericin] results in increased expression of BAX mRNA |
CTD |
PMID:29203277 PMID:32956828 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
beauvericin results in increased expression of BCL2 mRNA [zearalenol co-treated with beauvericin] results in increased expression of BCL2 mRNA |
CTD |
PMID:29203277 PMID:32956828 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
beauvericin results in increased expression of BIRC2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
beauvericin results in increased expression of BIRC3 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Btf3l4 |
basic transcription factor 3-like 4 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of BTF3L4 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866
|
|
G |
C1qtnf3 |
C1q and TNF related 3 |
decreases expression |
ISO |
beauvericin results in decreased expression of C1QTNF3 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433
|
|
G |
C1qtnf6 |
C1q and TNF related 6 |
increases expression |
ISO |
beauvericin results in increased expression of C1QTNF6 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of CAAP1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
|
|
G |
Card11 |
caspase recruitment domain family, member 11 |
decreases expression |
ISO |
beauvericin results in decreased expression of CARD11 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr12:13,621,140...13,758,115
Ensembl chr12:13,621,087...13,758,112
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
beauvericin results in increased activity of CASP3 protein [zearalenol co-treated with beauvericin] results in increased expression of CASP3 mRNA |
CTD |
PMID:25178661 PMID:32956828 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
EXP |
beauvericin results in increased activity of CASP7 protein |
CTD |
PMID:25178661 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
beauvericin results in increased expression of CASP8 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
beauvericin results in increased expression of CASP9 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccar2 |
cell cycle and apoptosis regulator 2 |
decreases expression |
ISO |
beauvericin results in decreased expression of CCAR2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr15:45,212,797...45,228,001
Ensembl chr15:45,212,803...45,227,636
|
|
G |
Ccdc124 |
coiled-coil domain containing 124 |
decreases expression |
ISO |
beauvericin results in decreased expression of CCDC124 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564
|
|
G |
Ccdc180 |
coiled-coil domain containing 180 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CCDC180 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:60,154,883...60,223,508
Ensembl chr 5:60,154,910...60,223,522
|
|
G |
Ccdc86 |
coiled-coil domain containing 86 |
decreases expression |
ISO |
beauvericin results in decreased expression of CCDC86 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:207,590,167...207,596,547
Ensembl chr 1:207,590,168...207,596,544
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CCNG2 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CCT5 protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd47 |
Cd47 molecule |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CD47 protein |
CTD |
PMID:32407736 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd81 |
Cd81 molecule |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CD81 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cdk2ap2 |
cyclin-dependent kinase 2 associated protein 2 |
decreases expression |
ISO |
beauvericin results in decreased expression of CDK2AP2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CEBPB mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
beauvericin results in increased expression of CFLAR mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chchd2 |
coiled-coil-helix-coiled-coil-helix domain containing 2 |
decreases expression |
ISO |
beauvericin results in decreased expression of CHCHD2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr12:26,828,738...26,834,762
Ensembl chr12:26,828,736...26,834,755
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of CIAPIN1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CNP protein |
CTD |
PMID:32407736 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Coa6 |
cytochrome c oxidase assembly factor 6 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of COA6 protein |
CTD |
PMID:32407736 |
|
NCBI chr19:54,395,746...54,398,348
Ensembl chr19:54,395,742...54,399,407
|
|
G |
Coro1c |
coronin 1C |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CORO1C protein |
CTD |
PMID:32407736 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of COTL1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cplane2 |
ciliogenesis and planar polarity effector complex subunit 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of CPLANE2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:153,515,507...153,516,455
Ensembl chr 5:153,515,376...153,522,508
|
|
G |
Cpne1 |
copine 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of CPNE1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 3:144,587,531...144,629,911
Ensembl chr 3:144,588,995...144,598,636
|
|
G |
Crim1 |
cysteine rich transmembrane BMP regulator 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CRIM1 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259
|
|
G |
Csdc2 |
cold shock domain containing C2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CSDC2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:113,451,998...113,466,464
Ensembl chr 7:113,451,998...113,466,463
|
|
G |
Csk |
C-terminal Src kinase |
decreases expression |
ISO |
beauvericin results in decreased expression of CSK mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ctps1 |
CTP synthase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CTPS1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CTSD protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cyp4f39 |
cytochrome P450, family 4, subfamily f, polypeptide 39 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of CYP4F22 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of DCXR protein |
CTD |
PMID:32407736 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
decreases expression |
ISO |
beauvericin results in decreased expression of DDIAS mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462
|
|
G |
Ddx47 |
DEAD-box helicase 47 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of DDX47 protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:167,845,652...167,858,115
Ensembl chr 4:167,845,640...167,859,115
|
|
G |
Dhrs7 |
dehydrogenase/reductase 7 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of DHRS7 protein |
CTD |
PMID:32407736 |
|
NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
increases expression |
ISO |
beauvericin results in increased expression of EDEM1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
beauvericin results in decreased expression of EIF5A mRNA |
CTD |
PMID:29203277 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
increases expression |
ISO |
beauvericin results in increased expression of FAIM2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|
G |
Fmc1 |
formation of mitochondrial complex V assembly factor 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of FMC1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140
|
|
G |
Gaa |
alpha glucosidase |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of GAA protein |
CTD |
PMID:32407736 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of GNA14 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of GNAI3 protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnb1 |
G protein subunit beta 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of GNB1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124
|
|
G |
Golga1 |
golgin A1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of GOLGA1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 3:22,765,690...22,812,637
Ensembl chr 3:22,767,761...22,812,585
|
|
G |
Gpnmb |
glycoprotein nmb |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of GPNMB protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of GPR18 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr15:98,997,427...99,001,177
Ensembl chr15:98,997,259...99,001,470
|
|
G |
Hexb |
hexosaminidase subunit beta |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of HEXB protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of HIST2H2BE protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:183,780,583...183,783,030
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of HNRNPM protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Hnrnpu |
heterogeneous nuclear ribonucleoprotein U |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of HNRNPU protein |
CTD |
PMID:32407736 |
|
NCBI chr13:90,069,058...90,086,905
Ensembl chr13:90,074,181...90,086,588
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of HSPA5 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Immt |
inner membrane mitochondrial protein |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of IMMT protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:103,880,482...103,919,116
Ensembl chr 4:103,880,459...103,919,109
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
beauvericin results in increased expression of INSIG1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Islr2 |
immunoglobulin superfamily containing leucine-rich repeat 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of ISLR2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 8:58,608,165...58,616,246
Ensembl chr 8:58,608,709...58,614,650
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of ITGB1 protein |
CTD |
PMID:32407736 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Klf12 |
KLF transcription factor 12 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of KLF12 protein |
CTD |
PMID:32407736 |
|
NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of KPNB1 protein |
CTD |
PMID:32407736 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of KRT16 protein |
CTD |
PMID:32407736 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt27 |
keratin 27 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of KRT27 protein |
CTD |
PMID:32407736 |
|
NCBI chr10:84,298,684...84,303,967
Ensembl chr10:84,298,508...84,303,967
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of KRT5 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Krt76 |
keratin 76 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of KRT76 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:133,016,990...133,025,475
Ensembl chr 7:133,016,992...133,025,496
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of LAMP2 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lat |
linker for activation of T cells |
decreases expression |
ISO |
beauvericin results in decreased expression of LAT mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:180,936,536...180,941,561
Ensembl chr 1:180,936,534...180,941,578
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
beauvericin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:25178661 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
EXP |
beauvericin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:25178661 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Matn4 |
matrilin 4 |
decreases expression |
ISO |
beauvericin results in decreased expression of MATN4 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 3:153,120,605...153,135,628
Ensembl chr 3:153,120,632...153,135,865
|
|
G |
Mavs |
mitochondrial antiviral signaling protein |
increases expression |
ISO |
beauvericin results in increased expression of MAVS mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 3:118,451,650...118,466,094
Ensembl chr 3:118,451,743...118,466,094
|
|
G |
Med6 |
mediator complex subunit 6 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of MED6 protein |
CTD |
PMID:32407736 |
|
NCBI chr 6:101,270,410...101,283,929
Ensembl chr 6:101,270,410...101,283,876
|
|
G |
Moap1 |
modulator of apoptosis 1 |
increases expression |
ISO |
beauvericin results in increased expression of MOAP1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 6:121,882,565...121,884,500
Ensembl chr 6:121,882,366...121,898,643
|
|
G |
Mrpl12 |
mitochondrial ribosomal protein L12 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of MRPL12 mRNA [beauvericin co-treated with enniatins] results in decreased expression of MRPL12 mRNA |
CTD |
PMID:29203277 PMID:31100301 |
|
NCBI chr10:105,758,410...105,762,913
Ensembl chr10:105,758,410...105,762,913
|
|
G |
Mrpl4 |
mitochondrial ribosomal protein L4 |
decreases expression |
ISO |
beauvericin results in decreased expression of MRPL4 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:19,539,593...19,545,608
Ensembl chr 8:19,539,593...19,545,608
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ATP6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ATP6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP6 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of ATP6 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ATP6 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-atp8 |
mitochondrially encoded ATP synthase membrane subunit 8 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ATP8 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ATP8 mRNA; [beauvericin co-treated with enniatins] affects the expression of ATP8 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of ATP8 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ATP8 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961 NCBI chr MT:7,758...7,961
Ensembl chr MT:7,758...7,961
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions decreases expression |
ISO |
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX1 mRNA; [beauvericin co-treated with enniatins] affects the expression of COX1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of COX1 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of COX1 mRNA beauvericin results in decreased expression of COX1 mRNA |
CTD |
PMID:31100301 PMID:34015425 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of COX3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of COX3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of COX3 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of COX3 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Mt-cyb |
mitochondrially encoded cytochrome b |
decreases expression |
ISO |
beauvericin results in decreased expression of CYTB mRNA |
CTD |
PMID:29203277 |
|
NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
|
|
G |
Mt-nd2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
decreases expression increases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND2 mRNA beauvericin results in increased expression of ND2 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND2 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND2 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in increased expression of ND2 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
|
|
G |
Mt-nd3 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 |
decreases expression increases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND3 mRNA beauvericin results in increased expression of ND3 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND3 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND3 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in increased expression of ND3 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798 NCBI chr MT:9,451...9,798
Ensembl chr MT:9,451...9,798
|
|
G |
Mt-nd4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND4 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4 mRNA; [beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND4 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of ND4 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G |
Mt-nd4l |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L |
decreases expression increases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND4L mRNA beauvericin results in increased expression of ND4L mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND4L mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND4L mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND4L mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND4L mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166 NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166
|
|
G |
Mt-nd5 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 |
decreases expression increases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND5 mRNA beauvericin results in increased expression of ND5 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of ND5 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND5 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND5 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND5 mRNA |
CTD |
PMID:29203277 PMID:31100301 PMID:34015425 |
|
NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of ND6 mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of ND6 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of ND6 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of ND6 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of ND6 mRNA |
CTD |
PMID:34015425 |
|
NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Mtrf1l |
mitochondrial translation release factor 1 like |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of MTRF1L protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:42,208,553...42,221,020
Ensembl chr 1:42,210,583...42,220,836
|
|
G |
Myo18a |
myosin XVIIIa |
increases expression |
ISO |
beauvericin results in increased expression of MYO18A mRNA |
CTD |
PMID:29203277 |
|
NCBI chr10:62,654,218...62,755,465
Ensembl chr10:62,654,281...62,755,468
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of NARS1 protein |
CTD |
PMID:32407736 |
|
NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622
|
|
G |
Nars2 |
asparaginyl-tRNA synthetase 2, mitochondrial |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of NARS2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:151,300,446...151,412,086
Ensembl chr 1:151,300,467...151,413,521
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of NDRG1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
increases expression |
ISO |
beauvericin results in increased expression of NLRP1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nod1 |
nucleotide-binding oligomerization domain containing 1 |
increases expression |
ISO |
beauvericin results in increased expression of NOD1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:84,060,871...84,111,668
Ensembl chr 4:84,060,880...84,111,404
|
|
G |
Nol3 |
nucleolar protein 3 |
increases expression |
ISO |
beauvericin results in increased expression of NOL3 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of NQO1 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nudt1 |
nudix hydrolase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of NUDT1 protein |
CTD |
PMID:32407736 |
|
NCBI chr12:14,302,514...14,309,559
Ensembl chr12:14,302,694...14,305,826
|
|
G |
Oga |
O-GlcNAcase |
increases expression |
ISO |
beauvericin results in increased expression of OGA mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases expression |
ISO |
beauvericin results in increased expression of OGT mRNA |
CTD |
PMID:29203277 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
multiple interactions increases expression |
ISO |
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of OSGIN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of OSGIN1 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of OSGIN1 mRNA beauvericin results in increased expression of OSGIN1 mRNA |
CTD |
PMID:31100301 PMID:34015425 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
Ostc |
oligosaccharyltransferase complex non-catalytic subunit |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of OSTC protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:219,250,549...219,266,076
Ensembl chr 2:219,236,952...219,266,107
|
|
G |
Parvg |
parvin, gamma |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PARVG protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:115,456,183...115,475,707
Ensembl chr 7:115,456,209...115,475,104
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
decreases expression |
ISO |
beauvericin results in decreased expression of PAWR mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
beauvericin results in decreased expression of PDCD11 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:245,980,840...246,021,999
Ensembl chr 1:245,980,880...246,021,999
|
|
G |
Pdcd2 |
programmed cell death 2 |
decreases expression |
ISO |
beauvericin results in decreased expression of PDCD2 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:56,484,947...56,490,437
Ensembl chr 1:56,463,931...56,490,437
|
|
G |
Pdcd2l |
programmed cell death 2-like |
increases expression |
ISO |
beauvericin results in increased expression of PDCD2L mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:86,810,292...86,822,554
Ensembl chr 1:86,810,292...86,822,554
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression |
ISO |
beauvericin results in decreased expression of PDCD4 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pdcd5 |
programmed cell death 5 |
increases expression |
ISO |
beauvericin results in increased expression of PDCD5 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:88,305,869...88,311,200
Ensembl chr 1:88,305,869...88,311,200
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
increases expression |
ISO |
beauvericin results in increased expression of PDCD6IP mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
beauvericin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pfn1 |
profilin 1 |
decreases expression multiple interactions |
ISO |
beauvericin results in decreased expression of PFN1 mRNA [beauvericin co-treated with enniatins] results in increased expression of PFN1 protein |
CTD |
PMID:29203277 PMID:32407736 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PGAM1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PGK1 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PHGDH protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phka2 |
phosphorylase kinase regulatory subunit alpha 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of PHKA2 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:34,170,959...34,293,498
Ensembl chr X:34,171,323...34,293,466
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of PIDD1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of PLK1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pls3 |
plastin 3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of PLS3 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PPA1 protein |
CTD |
PMID:32407736 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppan |
peter pan homolog |
decreases expression |
ISO |
beauvericin results in decreased expression of PPAN mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:19,423,908...19,427,941
Ensembl chr 8:19,423,961...19,427,938
|
|
G |
Ppib |
peptidylprolyl isomerase B |
decreases expression |
ISO |
beauvericin results in decreased expression of PPIB mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 8:66,603,877...66,609,734
Ensembl chr 8:66,603,861...66,630,428
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
decreases expression |
ISO |
beauvericin results in decreased expression of PPP1R14B mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of PPT1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PRKCA protein |
CTD |
PMID:32407736 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Psma5 |
proteasome 20S subunit alpha 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PSMA5 protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:195,896,365...195,919,731
|
|
G |
Psme4 |
proteasome activator subunit 4 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of PSME4 protein |
CTD |
PMID:32407736 |
|
NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PTGES3 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of PTPRC protein |
CTD |
PMID:32407736 |
|
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
|
|
G |
Rab11fip5 |
RAB11 family interacting protein 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of RAB11FIP5 protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:117,871,301...117,908,819
Ensembl chr 4:117,871,308...117,908,741
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RAB5A protein |
CTD |
PMID:32407736 |
|
NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
|
|
G |
Rac3 |
Rac family small GTPase 3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RAC3 protein |
CTD |
PMID:32407736 |
|
NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RAP1A protein |
CTD |
PMID:32407736 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Relt |
RELT, TNF receptor |
decreases expression |
ISO |
beauvericin results in decreased expression of RELT mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 1:155,206,976...155,224,609
Ensembl chr 1:155,206,976...155,214,196
|
|
G |
Rp2 |
RP2 activator of ARL3 GTPase |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RP2 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:1,872,582...1,916,704
Ensembl chr X:1,873,306...1,916,688
|
|
G |
Rpl37a |
ribosomal protein L37A |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RPL37A protein |
CTD |
PMID:32407736 |
|
NCBI chr 9:74,298,843...74,300,926
|
|
G |
Rpl5 |
ribosomal protein L5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RPL5 protein |
CTD |
PMID:32407736 |
|
NCBI chr14:1,843,856...1,850,301
Ensembl chr14:1,843,770...1,850,290
|
|
G |
Rpl8 |
ribosomal protein L8 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of RPL8 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482 Ensembl chr 3:108,622,324...108,628,482
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of RXRA protein |
CTD |
PMID:32407736 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Scml2 |
Scm polycomb group protein like 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of SCML2 protein |
CTD |
PMID:32407736 |
|
NCBI chr X:33,523,179...33,677,672
Ensembl chr X:33,524,530...33,652,742
|
|
G |
Sdf2l1 |
stromal cell-derived factor 2-like 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of SDF2L1 protein |
CTD |
PMID:32407736 |
|
NCBI chr11:83,872,659...83,874,902
Ensembl chr11:83,872,659...83,874,902
|
|
G |
Sdr42e2 |
short chain dehydrogenase/reductase family 42E, member 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SDR42E2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:175,361,630...175,382,769
Ensembl chr 1:175,362,150...175,382,050
|
|
G |
Sec13 |
SEC13 homolog, nuclear pore and COPII coat complex component |
decreases expression |
ISO |
beauvericin results in decreased expression of SEC13 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:146,877,739...146,891,130
Ensembl chr 4:146,875,524...146,891,173
|
|
G |
Siva1 |
SIVA1, apoptosis-inducing factor |
decreases expression |
ISO |
beauvericin results in decreased expression of SIVA1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 6:131,705,323...131,709,697
Ensembl chr 6:131,705,323...131,709,690
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SLC1A5 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SLC2A1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SLC3A2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SNRPD2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
|
|
G |
Snrpd3 |
small nuclear ribonucleoprotein D3 polypeptide |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of SNRPD3 protein |
CTD |
PMID:32407736 |
|
NCBI chr20:13,130,112...13,145,947
Ensembl chr20:13,130,119...13,145,978
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases activity |
EXP |
beauvericin results in decreased activity of SRC protein |
CTD |
PMID:25178661 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srm |
spermidine synthase |
decreases expression |
ISO |
beauvericin results in decreased expression of SRM mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 5:159,025,875...159,029,076
Ensembl chr 5:159,025,873...159,029,405
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of SRSF7 protein |
CTD |
PMID:32407736 |
|
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions decreases expression |
ISO |
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in decreased expression of SRXN1 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in decreased expression of SRXN1 mRNA; [Plant Extracts co-treated with beauvericin] results in decreased expression of SRXN1 mRNA beauvericin results in decreased expression of SRXN1 mRNA |
CTD |
PMID:31100301 PMID:34015425 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Ssbp1 |
single stranded DNA binding protein 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of SSBP1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135
|
|
G |
Tbc1d2b |
TBC1 domain family, member 2B |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TBC1D2B protein |
CTD |
PMID:32407736 |
|
NCBI chr 8:90,746,220...90,814,867
Ensembl chr 8:90,746,233...90,814,832
|
|
G |
Tcn2 |
transcobalamin 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TCN2 protein |
CTD |
PMID:32407736 |
|
NCBI chr14:78,813,343...78,828,549
Ensembl chr14:78,813,343...78,828,489
|
|
G |
Tcp11l1 |
t-complex 11 like 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TCP11L1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 3:91,047,006...91,092,687
Ensembl chr 3:90,998,270...91,092,006
|
|
G |
Tcp11l2 |
t-complex 11 like 2 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TCP11L2 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:19,150,241...19,185,135
Ensembl chr 7:19,150,252...19,185,095
|
|
G |
Thyn1 |
thymocyte nuclear protein 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of THYN1 protein |
CTD |
PMID:32407736 |
|
NCBI chr 8:25,406,563...25,415,445
Ensembl chr 8:25,406,500...25,415,445
|
|
G |
Timm9 |
translocase of inner mitochondrial membrane 9 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TIMM9 protein |
CTD |
PMID:32407736 |
|
NCBI chr 6:89,610,094...89,622,924
Ensembl chr 6:89,610,094...89,622,924
|
|
G |
Tk1 |
thymidine kinase 1 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TK1 protein |
CTD |
PMID:32407736 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tmem263 |
transmembrane protein 263 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TMEM263 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:18,610,151...18,628,311
Ensembl chr 7:18,610,149...18,628,534
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases expression |
ISO |
beauvericin results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tomm22 |
translocase of outer mitochondrial membrane 22 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TOMM22 protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:111,223,508...111,228,671
Ensembl chr 7:111,216,571...111,246,799
|
|
G |
Tomm7 |
translocase of outer mitochondrial membrane 7 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of TOMM7 protein |
CTD |
PMID:32407736 |
|
NCBI chr 4:11,305,122...11,311,963
Ensembl chr 4:11,305,110...11,311,962
|
|
G |
Tuba1b |
tubulin, alpha 1B |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TUBA1B protein |
CTD |
PMID:32407736 |
|
NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TUBB3 protein |
CTD |
PMID:32407736 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TUBB4A protein |
CTD |
PMID:32407736 |
|
NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Tubb4b |
tubulin, beta 4B class IVb |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TUBB4B protein |
CTD |
PMID:32407736 |
|
NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of TUBB protein |
CTD |
PMID:32407736 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions decreases expression |
ISO |
beauvericin results in increased expression of TXNIP mRNA [beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of TXNIP mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of TXNIP mRNA beauvericin results in decreased expression of TXNIP mRNA |
CTD |
PMID:29203277 PMID:34015425 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions decreases expression |
ISO |
[beauvericin co-treated with enniatins co-treated with ochratoxin A] results in increased expression of UCP2 mRNA; [beauvericin co-treated with enniatins] results in decreased expression of UCP2 mRNA; [Plant Extracts co-treated with beauvericin co-treated with enniatins] results in increased expression of UCP2 mRNA; [Plant Extracts co-treated with beauvericin] results in increased expression of UCP2 mRNA; [Plant Extracts co-treated with ochratoxin A co-treated with Zearalenone co-treated with beauvericin] results in decreased expression of UCP2 mRNA beauvericin results in decreased expression of UCP2 mRNA |
CTD |
PMID:31100301 PMID:34015425 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in decreased expression of UCP3 mRNA |
CTD |
PMID:31100301 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Ybx1 |
Y box binding protein 1 |
decreases expression |
ISO |
beauvericin results in decreased expression of YBX1 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 5:132,882,137...132,898,885
Ensembl chr 5:132,882,145...132,898,862
|
|
G |
Ybx3 |
Y box binding protein 3 |
decreases expression |
ISO |
beauvericin results in decreased expression of YBX3 mRNA |
CTD |
PMID:29203277 |
|
NCBI chr 4:165,129,747...165,153,101
Ensembl chr 4:165,129,758...165,153,161
|
|
G |
Ykt6 |
YKT6 v-SNARE homolog |
multiple interactions |
ISO |
[beauvericin co-treated with enniatins] results in increased expression of YKT6 protein |
CTD |
PMID:32407736 |
|
NCBI chr14:80,832,187...80,843,394
Ensembl chr14:80,832,187...80,843,385
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases activity |
EXP |
Carbon Monoxide results in increased activity of ABCC2 protein |
CTD |
PMID:13678533 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein; [Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein [Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased expression of PECAM1 protein; Carbon Monoxide results in increased expression of ADIPOQ protein |
CTD |
PMID:19356108 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
increases expression |
EXP |
Carbon Monoxide results in increased expression of ADM mRNA; Carbon Monoxide results in increased expression of ADM protein |
CTD |
PMID:10666155 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of AGR2 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
ISO |
AGT protein results in decreased susceptibility to Carbon Monoxide |
CTD |
PMID:18174886 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
AKT1 protein affects the reaction [Carbon Monoxide results in increased localization of NRF1 protein]; Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]; Carbon Monoxide results in increased phosphorylation of and results in increased activity of AKT1 protein; CAT protein inhibits the reaction [Carbon Monoxide results in increased phosphorylation of AKT1 protein] Carbon Monoxide inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein; Carbon Monoxide results in increased phosphorylation of and results in increased activity of AKT1 protein; CAT protein inhibits the reaction [Carbon Monoxide results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:17179207 PMID:18037988 PMID:18215737 PMID:18845810 PMID:19356108 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
increases activity multiple interactions |
EXP |
Carbon Monoxide results in increased activity of ALAD protein Carbon Monoxide inhibits the reaction [[Phenobarbital co-treated with bromobenzene] results in decreased activity of ALAD protein] |
CTD |
PMID:1032310 PMID:6740708 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in decreased expression of AREG mRNA |
CTD |
PMID:29621558 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
decreases phosphorylation |
ISO |
Carbon Monoxide results in decreased phosphorylation of BACH1 protein |
CTD |
PMID:18845810 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:18037988 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; MAPK14 protein affects the reaction [BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]] |
CTD |
PMID:11880364 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions decreases expression |
EXP |
Carbon Monoxide results in decreased expression of and results in decreased secretion of BDNF protein Carbon Monoxide results in decreased expression of BDNF mRNA |
CTD |
PMID:27113706 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; MAPK14 protein affects the reaction [BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]] |
CTD |
PMID:11880364 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP ISO |
[Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; Carbon Monoxide inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; sulforaphane inhibits the reaction [Carbon Monoxide results in increased expression of CASP3 mRNA]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] Carbon Monoxide results in increased expression of CASP3 protein [Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of CASP3 mRNA Carbon Monoxide results in increased activity of CASP3 protein |
CTD |
PMID:17173083 PMID:19356108 PMID:19520142 PMID:25562542 PMID:31268311 PMID:37860845 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
EXP |
Carbon Monoxide results in increased activity of CASP7 protein |
CTD |
PMID:25562542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
EXP ISO |
Carbon Monoxide results in increased activity of CASP8 protein [Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of CASP8 mRNA |
CTD |
PMID:25562542 PMID:31268311 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases expression |
EXP ISO |
Carbon Monoxide results in increased activity of CASP9 protein sulforaphane inhibits the reaction [Carbon Monoxide results in increased expression of CASP9 mRNA]; sulforaphane inhibits the reaction [Carbon Monoxide results in increased expression of CASP9 protein] Carbon Monoxide results in increased expression of CASP9 mRNA; Carbon Monoxide results in increased expression of CASP9 protein [Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of CASP9 mRNA |
CTD |
PMID:25562542 PMID:31268311 PMID:37860845 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
ISO EXP |
CAT protein inhibits the reaction [Carbon Monoxide results in increased localization of NFE2L2 protein]; CAT protein inhibits the reaction [Carbon Monoxide results in increased phosphorylation of AKT1 protein] Carbon Monoxide results in decreased expression of CAT protein CAT protein inhibits the reaction [Carbon Monoxide promotes the reaction [NRF1 protein binds to TFAM promoter]]; CAT protein inhibits the reaction [Carbon Monoxide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NFE2L2 protein inhibits the reaction [Carbon Monoxide results in decreased expression of CAT protein] |
CTD |
PMID:17179207 PMID:18845810 PMID:34032369 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in decreased expression of CCL1 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
EXP |
Carbon Monoxide results in decreased expression of CD86 protein |
CTD |
PMID:12201358 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of CLCA1 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of COL11A1 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Carbon Monoxide results in increased expression of CRP protein |
CTD |
PMID:18629312 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of CXCL11 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Carbon Monoxide inhibits the reaction [CYP1A1 protein results in increased reduction of sodium chromate(VI)] |
CTD |
PMID:1903091 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Carbon Monoxide promotes the reaction [1-ethynylpyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:10581206 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
Carbon Monoxide inhibits the reaction [CYP2B1 protein results in increased reduction of sodium chromate(VI)] |
CTD |
PMID:1903091 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
ISO EXP |
Carbon Monoxide results in decreased activity of CYP2E1 protein Carbon Monoxide inhibits the reaction [CYP2E1 protein results in increased reduction of sodium chromate(VI)] |
CTD |
PMID:1903091 PMID:15036350 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions increases expression |
EXP |
sulforaphane inhibits the reaction [Carbon Monoxide results in increased expression of DNM1L protein] |
CTD |
PMID:37860845 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Duox2 |
dual oxidase 2 |
increases expression decreases expression |
EXP |
Carbon Monoxide results in increased expression of DUOX2 mRNA Carbon Monoxide results in decreased expression of DUOX2 protein |
CTD |
PMID:29223502 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
EXP ISO |
Carbon Monoxide results in increased expression of EDN1 mRNA; Carbon Monoxide results in increased expression of EDN1 protein Carbon Monoxide deficiency promotes the reaction [HMOX2 mutant form results in increased expression of EDN1 protein] |
CTD |
PMID:11781074 PMID:12969895 PMID:20197249 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA]; Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 protein]; UCP2 protein promotes the reaction [Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 protein]] |
CTD |
PMID:22046279 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Carbon Monoxide results in increased expression of EPO mRNA; Carbon Monoxide results in increased expression of EPO protein |
CTD |
PMID:9263988 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
EXP |
Carbon Monoxide results in increased expression of ERO1A mRNA |
CTD |
PMID:12752442 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[[Vehicle Emissions results in increased abundance of Air Pollutants] which results in increased abundance of Carbon Monoxide] which results in decreased expression of EZR protein |
CTD |
PMID:37141245 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions |
ISO |
FGB gene SNP affects the reaction [Carbon Monoxide results in increased expression of IL6 protein] |
CTD |
PMID:19750100 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of Carbon Monoxide] which affects the methylation of FOXP3 gene; [Air Pollutants results in increased abundance of Carbon Monoxide] which results in increased methylation of FOXP3 promoter |
CTD |
PMID:29317916 PMID:33603036 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
increases expression multiple interactions |
ISO EXP |
Carbon Monoxide results in increased expression of GABPA mRNA Carbon Monoxide results in increased expression of GABPA protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Carbon Monoxide results in increased expression of GABPA protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide results in increased expression of GABPA protein]; Carbon Monoxide promotes the reaction [GABPA protein binds to TFAM promoter] |
CTD |
PMID:17179207 |
|
NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased activity of GATA4 protein] |
CTD |
PMID:18037988 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
Carbon Monoxide results in increased expression of GCLC mRNA [NFE2L2 protein co-treated with Carbon Monoxide] results in increased expression of GCLC mRNA |
CTD |
PMID:34032369 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpr182 |
G protein-coupled receptor 182 |
increases expression |
EXP |
Carbon Monoxide results in increased expression of GPR182 mRNA |
CTD |
PMID:10666155 |
|
NCBI chr 7:63,585,997...63,589,088
Ensembl chr 7:63,578,750...63,589,210
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased expression of GPX4 protein] |
CTD |
PMID:18037988 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased phosphorylation of GSK3B protein] Carbon Monoxide results in increased phosphorylation of GSK3B protein |
CTD |
PMID:18037988 PMID:18845810 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases chemical synthesis increases expression increases activity |
ISO EXP |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein]; Carbon Monoxide inhibits the reaction [IFNG protein results in decreased expression of HMOX1 protein]; HMOX1 protein affects the reaction [Carbon Monoxide results in increased secretion of IL10 protein]; HMOX1 protein promotes the reaction [Carbon Monoxide results in increased expression of IL22 mRNA]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased chemical synthesis of Carbon Monoxide [HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein; [RELA protein co-treated with REL protein] inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; MAPK14 protein affects the reaction [BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; MAPK14 protein affects the reaction [BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; RELA protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]] Carbon Monoxide results in increased expression of HMOX1 protein Edaravone promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Carbon Monoxide results in increased activity of HMOX1 protein] |
CTD |
PMID:11880364 PMID:16365149 PMID:18037988 PMID:18845810 PMID:19520142 PMID:21444764 PMID:25348283 PMID:29165873 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions affects chemical synthesis affects abundance |
EXP |
Carbon Monoxide deficiency promotes the reaction [HMOX2 mutant form results in increased expression of EDN1 protein] HMOX2 protein affects the chemical synthesis of Carbon Monoxide HMOX2 protein affects the abundance of Carbon Monoxide |
CTD |
PMID:11342580 PMID:12969895 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP ISO |
[Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:19356108 PMID:19608869 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in decreased expression of IFNG protein; Carbon Monoxide inhibits the reaction [IFNG protein promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein]]; Carbon Monoxide inhibits the reaction [IFNG protein results in decreased expression of HMOX1 protein] [Air Pollutants results in increased abundance of Carbon Monoxide] which affects the methylation of IFNG gene |
CTD |
PMID:16365149 PMID:29621558 PMID:33603036 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Carbon Monoxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; HMOX1 protein affects the reaction [Carbon Monoxide results in increased secretion of IL10 protein] [Air Pollutants results in increased abundance of Carbon Monoxide] which affects the methylation of IL10 gene (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein]] Carbon Monoxide results in increased expression of IL10 mRNA |
CTD |
PMID:21444764 PMID:31732924 PMID:33603036 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [IFNG protein promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein]] |
CTD |
PMID:16365149 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in decreased expression of IL13 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL17A protein |
CTD |
PMID:29621558 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
decreases response to substance multiple interactions |
ISO |
Carbon Monoxide results in decreased susceptibility to IL18 protein Carbon Monoxide inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Carbon Monoxide inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions increases expression |
ISO EXP |
Carbon Monoxide results in decreased expression of IL1B protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein]] |
CTD |
PMID:21444764 PMID:31732924 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
increases expression multiple interactions |
EXP |
Carbon Monoxide results in increased expression of IL1RL1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein]] |
CTD |
PMID:31732924 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il33 |
interleukin 33 |
multiple interactions increases expression |
EXP |
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]] |
CTD |
PMID:31732924 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
decreases expression multiple interactions |
ISO EXP |
Carbon Monoxide results in decreased expression of IL4 protein [Air Pollutants results in increased abundance of Carbon Monoxide] which affects the methylation of IL4 gene [Carbon Monoxide co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in increased expression of IL4 protein; iodopravadoline inhibits the reaction [[Carbon Monoxide co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in increased expression of IL4 protein] [Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL4 protein |
CTD |
PMID:21444764 PMID:29621558 PMID:31732924 PMID:33603036 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased secretion of IL6 protein; Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of IL6 protein]; FGB gene SNP affects the reaction [Carbon Monoxide results in increased expression of IL6 protein]; IL6 gene SNP affects the reaction [Carbon Monoxide results in increased expression of IL6 protein] |
CTD |
PMID:18629312 PMID:19608869 PMID:19750100 PMID:31268311 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf8 |
interferon regulatory factor 8 |
decreases activity |
ISO |
Carbon Monoxide results in decreased activity of IRF8 protein |
CTD |
PMID:16365149 |
|
NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [NFE2L2 protein binds to KEAP1 protein] |
CTD |
PMID:18845810 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
MAPK14 protein affects the reaction [BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; MAPK14 protein affects the reaction [BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]] |
CTD |
PMID:11880364 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mbp |
myelin basic protein |
affects response to substance |
ISO |
MBP polymorphism affects the susceptibility to Carbon Monoxide |
CTD |
PMID:36481359 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions decreases expression |
EXP |
sulforaphane affects the reaction [Carbon Monoxide results in decreased expression of MFN2 protein]; sulforaphane inhibits the reaction [Carbon Monoxide results in decreased expression of MFN2 mRNA] Carbon Monoxide results in decreased expression of MFN2 mRNA; Carbon Monoxide results in decreased expression of MFN2 protein |
CTD |
PMID:37860845 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir1224 |
microRNA 1224 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR1224 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr11:80,306,902...80,306,986
Ensembl chr11:80,306,902...80,306,986
|
|
G |
Mir186 |
microRNA 186 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR186 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR21 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir342 |
microRNA 342 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR342 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr 6:127,565,269...127,565,367
Ensembl chr 6:127,565,269...127,565,367
|
|
G |
Mir374b |
microRNA 374b |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR374B mRNA |
CTD |
PMID:31268311 |
|
NCBI chr X:68,591,732...68,591,799
Ensembl chr X:68,591,732...68,591,799
|
|
G |
Mir615 |
microRNA 615 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR615 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr 7:134,151,887...134,151,978
Ensembl chr 7:134,151,887...134,151,978
|
|
G |
Mir93 |
microRNA 93 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIR93 mRNA |
CTD |
PMID:31268311 |
|
NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221
|
|
G |
Mirlet7i |
microRNA let-7i |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased expression of MIRLET7I mRNA |
CTD |
PMID:31268311 |
|
NCBI chr 7:58,642,485...58,642,569
Ensembl chr 7:58,642,480...58,642,571
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
Carbon Monoxide results in increased expression of MMP9 mRNA |
CTD |
PMID:20197249 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Carbon Monoxide] results in increased expression of MRC1 protein; iodopravadoline inhibits the reaction [[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Carbon Monoxide] results in increased expression of MRC1 protein] |
CTD |
PMID:31732924 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [Oxygen deficiency results in increased expression of NDRG1 mRNA]; Carbon Monoxide inhibits the reaction [Oxygen deficiency results in increased expression of NDRG1 protein] |
CTD |
PMID:11006124 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression increases localization decreases phosphorylation |
ISO EXP |
Carbon Monoxide inhibits the reaction [NFE2L2 protein binds to KEAP1 protein]; Carbon Monoxide promotes the reaction [NFE2L2 protein binds to NRF1 promoter]; CAT protein inhibits the reaction [Carbon Monoxide results in increased localization of NFE2L2 protein]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased expression of SOD2 mRNA] Carbon Monoxide results in increased expression of NFE2L2 mRNA; Carbon Monoxide results in increased expression of NFE2L2 protein [NFE2L2 protein co-treated with Carbon Monoxide] results in increased expression of GCLC mRNA; Edaravone promotes the reaction [Carbon Monoxide results in increased expression of NFE2L2 protein]; NFE2L2 protein inhibits the reaction [Carbon Monoxide results in decreased expression of CAT protein]; NFE2L2 protein promotes the reaction [Carbon Monoxide results in increased expression of NFE2L2 mRNA] Carbon Monoxide results in decreased phosphorylation of NFE2L2 protein |
CTD |
PMID:18845810 PMID:25348283 PMID:34032369 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[RELA protein co-treated with REL protein] inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; MAPK14 protein affects the reaction [BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; MAPK14 protein affects the reaction [BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; RELA protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]] |
CTD |
PMID:11880364 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
affects expression multiple interactions |
EXP |
Carbon Monoxide affects the expression of NGF mRNA Carbon Monoxide results in decreased expression of and affects the secretion of NGF protein |
CTD |
PMID:27113706 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; PPARG protein promotes the reaction [Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] Carbon Monoxide results in decreased expression of NOS2 protein |
CTD |
PMID:12201358 PMID:22046279 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein |
CTD |
PMID:19356108 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
EXP |
Carbon Monoxide results in increased expression of NPPA mRNA |
CTD |
PMID:11781074 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions increases expression increases localization |
ISO EXP |
AKT1 protein affects the reaction [Carbon Monoxide results in increased localization of NRF1 protein]; Carbon Monoxide promotes the reaction [NFE2L2 protein binds to NRF1 promoter] Carbon Monoxide results in increased expression of NRF1 protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Carbon Monoxide results in increased expression of NRF1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide promotes the reaction [NRF1 protein binds to PPARGC1A protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide results in increased expression of NRF1 protein]; Carbon Monoxide promotes the reaction [NRF1 protein binds to PPARGC1A protein]; Carbon Monoxide promotes the reaction [NRF1 protein binds to TFAM promoter]; CAT protein inhibits the reaction [Carbon Monoxide promotes the reaction [NRF1 protein binds to TFAM promoter]] Carbon Monoxide results in increased expression of NRF1 mRNA |
CTD |
PMID:17179207 PMID:18845810 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Ntf3 |
neurotrophin 3 |
decreases expression multiple interactions |
EXP |
Carbon Monoxide results in decreased expression of NTF3 mRNA Carbon Monoxide results in decreased expression of and results in decreased secretion of NTF3 protein |
CTD |
PMID:27113706 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased expression of PECAM1 protein |
CTD |
PMID:19356108 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
affects expression |
ISO |
Carbon Monoxide affects the expression of PLA2G7 |
CTD |
PMID:21356620 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
increases expression |
ISO |
Carbon Monoxide results in increased expression of POLG mRNA; Carbon Monoxide results in increased expression of POLG protein |
CTD |
PMID:17179207 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[Carbon Monoxide results in increased abundance of Reactive Oxygen Species] which results in increased sumoylation of PPARG protein; Acetylcysteine inhibits the reaction [[Carbon Monoxide results in increased abundance of Reactive Oxygen Species] which results in increased sumoylation of PPARG protein]; PPARG protein promotes the reaction [Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] |
CTD |
PMID:22046279 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO EXP |
Carbon Monoxide results in increased expression of PPARGC1A mRNA Carbon Monoxide results in increased expression of PPARGC1A protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Carbon Monoxide results in increased expression of PPARGC1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide promotes the reaction [NRF1 protein binds to PPARGC1A protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide results in increased expression of PPARGC1A protein]; Carbon Monoxide promotes the reaction [NRF1 protein binds to PPARGC1A protein] |
CTD |
PMID:17179207 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prg2 |
proteoglycan 2, pro eosinophil major basic protein |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of PRG2 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr 3:70,062,535...70,066,102
Ensembl chr 3:70,062,535...70,066,101
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions decreases expression |
EXP |
sulforaphane inhibits the reaction [Carbon Monoxide results in decreased expression of PRKAA2 mRNA] |
CTD |
PMID:37860845 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Carbon Monoxide inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[RELA protein co-treated with REL protein] inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]] |
CTD |
PMID:11880364 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[RELA protein co-treated with REL protein] inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; RELA protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]] |
CTD |
PMID:11880364 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Selp |
selectin P |
increases expression |
ISO |
Carbon Monoxide results in increased expression of SELP protein modified form |
CTD |
PMID:18629312 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sftpd |
surfactant protein D |
multiple interactions |
ISO |
[[Vehicle Emissions results in increased abundance of Air Pollutants] which results in increased abundance of Carbon Monoxide] which results in increased expression of SFTPD protein |
CTD |
PMID:37141245 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Carbon Monoxide results in decreased expression of SOD1 protein |
CTD |
PMID:18629312 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO EXP |
Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; NFE2L2 protein affects the reaction [Carbon Monoxide results in increased expression of SOD2 mRNA] Carbon Monoxide results in increased expression of SOD2 protein |
CTD |
PMID:17179207 PMID:18037988 PMID:18845810 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sostdc1 |
sclerostin domain containing 1 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of SOSTDC1 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression multiple interactions |
ISO EXP |
Carbon Monoxide results in increased expression of TFAM mRNA; Carbon Monoxide results in increased expression of TFAM protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [Carbon Monoxide results in increased expression of TFAM protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carbon Monoxide results in increased expression of TFAM protein]; Carbon Monoxide promotes the reaction [GABPA protein binds to TFAM promoter]; Carbon Monoxide promotes the reaction [NRF1 protein binds to TFAM promoter]; CAT protein inhibits the reaction [Carbon Monoxide promotes the reaction [NRF1 protein binds to TFAM promoter]] |
CTD |
PMID:17179207 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression decreases expression decreases response to substance |
EXP ISO |
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Carbon Monoxide inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]] Carbon monoxide decreases expression of Tnf mRNA in reperfused liver nonparenchymal cells Carbon Monoxide results in decreased susceptibility to TNF protein [Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides co-treated with Carbon Monoxide]] which results in increased secretion of TNF protein; [HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein; [RELA protein co-treated with REL protein] inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]; Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of IL6 protein]; Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; MAPK14 protein affects the reaction [BCL2A1 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; MAPK14 protein affects the reaction [BIRC3 protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]]]; RELA protein inhibits the reaction [NFKBIA protein inhibits the reaction [[HMOX1 protein results in increased chemical synthesis of Carbon Monoxide] which results in decreased susceptibility to TNF protein]] Carbon Monoxide results in decreased expression of TNF protein |
CTD RGD |
PMID:11880364 PMID:17173083 PMID:19356108 PMID:19608869 PMID:21444764 PMID:31268311 PMID:31732924 PMID:18972563 More...
|
RGD:15023490 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression |
ISO |
Carbon Monoxide results in increased expression of TNFRSF1B protein modified form |
CTD |
PMID:18629312 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
multiple interactions |
ISO |
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of TNFSF4 mRNA |
CTD |
PMID:29621558 |
|
NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
UCP2 protein promotes the reaction [Carbon Monoxide inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 protein]]; UCP2 protein promotes the reaction [Carbon Monoxide results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:22046279 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
decreases phosphorylation |
ISO |
Carbon Monoxide results in decreased phosphorylation of VASP protein |
CTD |
PMID:26582457 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO EXP |
Carbon Monoxide inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] [Carbon Monoxide results in increased expression of ADIPOQ protein] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:19356108 PMID:19608869 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Xdh |
xanthine dehydrogenase |
increases activity increases metabolic processing |
EXP |
Carbon Monoxide results in increased activity of XDH protein Carbon Monoxide results in increased metabolism of XDH protein |
CTD |
PMID:1447108 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport multiple interactions |
ISO |
ABCG2 protein affects the transport of Cimetidine Cimetidine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride] |
CTD |
PMID:15365089 PMID:15722455 PMID:26907376 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH1C protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH4 protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH5 protein results in increased oxidation of S-hydroxymethylglutathione] |
CTD |
PMID:23220590 |
|
NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH7 protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Cimetidine promotes the reaction [Metformin results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:20956498 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects expression multiple interactions |
ISO |
Cimetidine affects the expression of AHR protein [Monocrotophos co-treated with Cimetidine] results in increased expression of AHR protein |
CTD |
PMID:22733800 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ALDH1A1 protein results in increased oxidation of Acetaldehyde] |
CTD |
PMID:23220590 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ALDH3A1 protein results in increased oxidation of benzaldehyde] |
CTD |
PMID:23220590 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases activity |
ISO |
Cimetidine results in increased activity of APAF1 protein |
CTD |
PMID:17273750 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO EXP |
Cimetidine inhibits the reaction [Dihydrotestosterone binds to AR protein] Cimetidine results in decreased expression of AR protein |
CTD |
PMID:6835285 PMID:26021711 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Cimetidine results in increased expression of BAX protein Cimetidine inhibits the reaction [Ethanol results in increased expression of BAX protein] |
CTD |
PMID:20127008 PMID:27983966 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of BCL2 protein Cimetidine inhibits the reaction [Ethanol results in decreased expression of BCL2 protein] |
CTD |
PMID:20127008 PMID:27983966 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
ISO |
Cimetidine results in increased activity of CASP1 protein CASP1 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] |
CTD |
PMID:16723495 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of CASP12 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases expression |
ISO EXP |
Cimetidine results in increased activity of CASP3 protein Cimetidine inhibits the reaction [Ethanol results in increased expression of CASP3 protein] Cimetidine results in increased expression of CASP3 protein |
CTD |
PMID:17273750 PMID:20127008 PMID:26021711 PMID:27983966 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP7 protein |
CTD |
PMID:17273750 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP8 protein |
CTD |
PMID:17273750 PMID:20127008 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP9 protein |
CTD |
PMID:17273750 PMID:20127008 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein] |
CTD |
PMID:12107048 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Cimetidine results in decreased expression of CD14 protein |
CTD |
PMID:11556524 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Cisplatin results in increased expression of CST3] |
CTD |
PMID:22525860 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctsd |
cathepsin D |
decreases activity |
EXP |
Cimetidine results in decreased activity of CTSD protein |
CTD |
PMID:12903910 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases activity |
EXP |
Cimetidine results in decreased activity of CTSL protein |
CTD |
PMID:12903910 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
ISO |
Cimetidine inhibits the reaction [Cocaine results in increased expression of CYP1A1 protein] Cimetidine results in decreased expression of CYP1A1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP1A1 protein Cimetidine results in decreased activity of CYP1A1 protein |
CTD |
PMID:11856816 PMID:22733800 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP1A2 protein] |
CTD |
PMID:7946932 PMID:19909766 PMID:31863871 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression multiple interactions decreases activity |
ISO |
Cimetidine results in decreased expression of CYP2B6 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP2B6 protein Cimetidine results in decreased activity of CYP2B6 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
Cimetidine inhibits the reaction [CYP2C11 protein results in increased glutathionylation of lamotrigine] |
CTD |
PMID:19961160 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity multiple interactions |
ISO EXP |
Cimetidine results in decreased activity of CYP2D6 protein Cimetidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan] styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2D6 protein] |
CTD |
PMID:17651725 PMID:19909766 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of CYP2E1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP2E1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Cocaine results in increased expression of CYP2J2 protein] |
CTD |
PMID:11856816 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases expression decreases activity |
ISO |
[Monocrotophos co-treated with Cimetidine] results in increased expression of CYP3A4 protein; Cimetidine inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Nifedipine]; styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP3A4 protein] Cimetidine results in decreased expression of CYP3A4 protein |
CTD |
PMID:2271712 PMID:16041596 PMID:18846481 PMID:19909766 PMID:22733800 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
affects expression |
ISO |
Cimetidine affects the expression of FSHB protein |
CTD |
PMID:435711 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gast |
gastrin |
affects expression |
ISO |
Cimetidine affects the expression of GAST protein |
CTD |
PMID:12503773 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects expression multiple interactions |
ISO |
Cimetidine affects the expression of GSTP1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of GSTP1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein] |
CTD |
PMID:12806184 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [HRH1 results in decreased susceptibility to Morphine] |
CTD |
PMID:14569158 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity increases expression |
ISO EXP |
[Cimetidine binds to and results in decreased activity of HRH2 protein] results in decreased susceptibility to [Histamine co-treated with [Oxygen deficiency co-treated with Oxygen]]; [Cimetidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Cimetidine binds to and results in decreased activity of HRH2 protein; Cimetidine binds to and results in increased activity of HRH2 protein; Cimetidine inhibits the reaction [HRH2 protein promotes the reaction [Histamine results in increased expression of IL16 protein]] Cimetidine results in decreased activity of HRH2 protein [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased susceptibility to clobenpropit; Cimetidine binds to and results in decreased activity of HRH2 protein; Cimetidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine] Cimetidine binds to and results in increased activity of HRH2 protein; Cimetidine inhibits the reaction [HRH2 results in decreased susceptibility to Morphine]; HRH2 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] Cimetidine results in increased expression of HRH2 protein |
CTD |
PMID:1912125 PMID:2461127 PMID:6522242 PMID:9681472 PMID:12235264 PMID:14569158 PMID:15961859 PMID:16488453 PMID:16632449 PMID:16723495 PMID:19215234 PMID:21276809 PMID:22926047 More...
|
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of ICAM1 protein |
CTD |
PMID:17189874 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
Cimetidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]] Cimetidine results in increased expression of IFNG mRNA; Cimetidine results in increased expression of IFNG protein |
CTD |
PMID:10569698 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [HRH2 protein promotes the reaction [Histamine results in increased expression of IL16 protein]] |
CTD |
PMID:12235264 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases expression |
ISO |
CASP1 protein affects the reaction [Cimetidine results in increased expression of IL18 protein]; Famotidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Ranitidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein] HRH2 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] |
CTD |
PMID:16723495 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:12065299 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itga4 |
integrin subunit alpha 4 |
decreases expression |
ISO |
Cimetidine results in decreased expression of ITGA4 protein |
CTD |
PMID:11556524 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itgax |
integrin subunit alpha X |
decreases expression |
ISO |
Cimetidine results in decreased expression of ITGAX protein |
CTD |
PMID:11556524 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of LRP1 protein |
CTD |
PMID:11556524 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of NCAM mRNA; Cimetidine results in decreased expression of NCAM protein |
CTD |
PMID:17273750 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:12065299 PMID:12107048 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of NR1I2 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of NR1I2 protein |
CTD |
PMID:22733800 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of NR1I3 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of NR1I3 protein |
CTD |
PMID:22733800 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
Cimetidine inhibits the reaction [Histamine results in increased expression of NTF3 protein] |
CTD |
PMID:21276809 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Histamine results in increased expression of PDE4B mRNA] |
CTD |
PMID:11131300 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Prl |
prolactin |
affects expression |
ISO |
Cimetidine affects the expression of PRL protein |
CTD |
PMID:435711 PMID:9037573 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prok1 |
prokineticin 1 |
decreases expression |
EXP |
Cimetidine results in decreased expression of PROK1 protein |
CTD |
PMID:26021711 |
|
NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein] Cimetidine inhibits the reaction [Ethanol results in increased expression of RELA protein] |
CTD |
PMID:12065299 PMID:12107048 PMID:24300194 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Selp |
selectin P |
decreases expression |
ISO |
Cimetidine results in decreased expression of SELP protein |
CTD |
PMID:17189874 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases uptake multiple interactions |
EXP ISO |
SLC22A1 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium] |
CTD |
PMID:16006492 PMID:19357179 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions increases transport decreases response to substance increases uptake |
ISO EXP |
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine]; Cimetidine inhibits the reaction [SLC22A2 protein affects the transport of Tetraethylammonium]; Cimetidine inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; p-Aminohippuric Acid inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine] SLC22A2 protein results in increased transport of Cimetidine SLC22A2 gene polymorphism results in decreased susceptibility to Cimetidine |
CTD |
PMID:15496291 PMID:16006492 PMID:18230276 PMID:19357179 PMID:21599003 PMID:22525860 More...
|
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions increases transport |
ISO |
Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin] Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] SLC22A3 protein results in increased transport of Cimetidine |
CTD |
PMID:10966924 PMID:18253050 PMID:19357179 PMID:21697722 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions increases uptake |
ISO |
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15496291 PMID:16006492 PMID:16098483 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases uptake multiple interactions |
ISO |
SLC22A7 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 PMID:16006492 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake affects transport |
ISO EXP |
Cimetidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Cimetidine] SLC22A8 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] estradiol-17 beta-glucuronide inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Cimetidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Ranitidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:15496291 PMID:16006492 PMID:16098483 More...
|
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
affects transport multiple interactions decreases activity |
ISO |
SLC47A1 protein affects the transport of Cimetidine Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of Cadmium] Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of Cadmium] Cimetidine results in decreased activity of SLC47A1 protein |
CTD |
PMID:16928787 PMID:21599003 PMID:27871888 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [SLC47A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC47A2 protein results in increased uptake of Cadmium] |
CTD |
PMID:21599003 PMID:27871888 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
multiple interactions |
EXP |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] |
CTD |
PMID:12806184 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Dimaprit inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Cimetidine inhibits the reaction [Cocaine results in increased expression of TNF protein] |
CTD |
PMID:9088875 PMID:11856816 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Cinacalcet results in decreased activity of CYP2D6 protein |
CTD |
PMID:16680561 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Cinacalcet results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression multiple interactions decreases ubiquitination |
ISO |
Cinacalcet results in increased expression of KLF2 protein [Cinacalcet inhibits the reaction [Adenine results in increased expression of TRAF2 protein]] which results in decreased ubiquitination of and results in decreased degradation of KLF2 protein; [Cinacalcet results in decreased expression of TRAF2 protein] which results in decreased ubiquitination of KLF2 protein; Cinacalcet inhibits the reaction [Adenine results in decreased expression of KLF2 protein]; TRAF2 protein inhibits the reaction [Cinacalcet results in increased expression of KLF2 protein] Cinacalcet results in decreased ubiquitination of KLF2 protein |
CTD |
PMID:35635602 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Pth |
parathyroid hormone |
decreases expression multiple interactions decreases secretion |
ISO |
Cinacalcet results in decreased expression of PTH protein [Cinacalcet co-treated with Vitamin D] results in decreased expression of PTH protein Cinacalcet results in decreased secretion of PTH protein |
CTD |
PMID:17060004 PMID:18256372 PMID:21541686 PMID:22118402 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions decreases expression |
ISO |
[Cinacalcet inhibits the reaction [Adenine results in increased expression of TRAF2 protein]] which results in decreased ubiquitination of and results in decreased degradation of KLF2 protein; [Cinacalcet results in decreased expression of TRAF2 protein] which results in decreased ubiquitination of KLF2 protein; Cinacalcet inhibits the reaction [Adenine results in increased expression of TRAF2 protein]; TRAF2 protein inhibits the reaction [Cinacalcet results in increased expression of KLF2 protein] Cinacalcet results in decreased expression of TRAF2 mRNA; Cinacalcet results in decreased expression of TRAF2 protein |
CTD |
PMID:35635602 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
|
G |
Ins2 |
insulin 2 |
increases secretion |
ISO |
Trimethoprim, Sulfamethoxazole Drug Combination results in increased secretion of INS protein modified form |
CTD |
PMID:14714756 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat |
CTD |
PMID:33629115 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of HSPA5 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat |
CTD |
PMID:33629115 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased susceptibility to Cobicistat |
CTD |
PMID:33629115 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:33629115 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases response to substance increases metabolic processing decreases activity increases expression |
ISO |
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18454852 PMID:19601638 PMID:21482471 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing increases expression decreases activity |
ISO |
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2C19 protein |
CTD |
PMID:21093571 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2D6 protein |
CTD |
PMID:21276781 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP3A4 protein |
CTD |
PMID:21276781 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [ADCYAP1 protein affects the secretion of Acids] |
CTD |
PMID:20388963 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in increased expression of AGT protein] |
CTD |
PMID:27645307 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases activity |
ISO |
Famotidine results in decreased activity of BRAF protein |
CTD |
PMID:20823850 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Car12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA12 protein |
CTD |
PMID:30344913 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA2 protein |
CTD |
PMID:30344913 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car6 |
carbonic anhydrase 6 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA6 protein |
CTD |
PMID:30344913 |
|
NCBI chr 5:160,658,104...160,676,644
Ensembl chr 5:160,658,105...160,676,644
|
|
G |
Car7 |
carbonic anhydrase 7 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA7 protein |
CTD |
PMID:30344913 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of CAT protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]] Famotidine inhibits the reaction [Indomethacin results in decreased expression of CAT protein] |
CTD |
PMID:18726076 PMID:19034656 PMID:19497431 PMID:25926722 PMID:38447874 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]] |
CTD |
PMID:12538815 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CTNNB1 mRNA] Famotidine results in increased expression of CTNNB1 mRNA |
CTD |
PMID:31563592 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Famotidine results in increased expression of CXCL1 protein |
CTD |
PMID:12023551 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole] |
CTD |
PMID:15963082 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA |
CTD |
PMID:17717918 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
Famotidine results in increased expression of FGF21 protein |
CTD |
PMID:8774986 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA] |
CTD |
PMID:9187264 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabra3 |
gamma-aminobutyric acid type A receptor subunit alpha 3 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr X:150,244,745...150,501,566
Ensembl chr X:150,261,607...150,501,559
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr14:37,396,217...37,469,606
Ensembl chr14:37,396,294...37,635,956
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gast |
gastrin |
affects expression increases expression |
ISO EXP |
Famotidine affects the expression of GAST protein Famotidine results in increased expression of GAST protein |
CTD |
PMID:12503773 PMID:17652263 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Famotidine inhibits the reaction [GHRL protein results in increased secretion of Acids] |
CTD |
PMID:16838121 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Famotidine inhibits the reaction [Dizocilpine Maleate results in increased expression of GSK3B mRNA] |
CTD |
PMID:31563592 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity increases expression |
ISO EXP |
[Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Famotidine binds to and results in decreased activity of HRH2 protein; Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA] Famotidine results in decreased activity of HRH2 protein [Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Histamine Famotidine results in increased expression of HRH2 protein |
CTD |
PMID:9187264 PMID:9681472 PMID:12832840 PMID:15961859 PMID:16632449 PMID:21276809 More...
|
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression multiple interactions |
EXP |
Famotidine results in decreased expression of HSPA1A protein Zinc Compounds analog inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein] |
CTD |
PMID:16945336 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:12538815 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]] Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:19277450 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]] |
CTD |
PMID:11752121 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]] |
CTD |
PMID:11752121 PMID:12364868 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]] |
CTD |
PMID:11752121 PMID:12364868 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:16723495 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
[Famotidine co-treated with Sucralfate] results in decreased expression of IL1B mRNA Famotidine inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of IL1B mRNA] |
CTD |
PMID:17717918 PMID:27474069 PMID:27645307 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]] |
CTD |
PMID:19277450 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]] |
CTD |
PMID:19277450 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of IL6 protein] |
CTD |
PMID:17603938 PMID:27474069 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17656145 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17656145 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; Famotidine inhibits the reaction [Histamine results in increased secretion of MMP1 protein] |
CTD |
PMID:17656145 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased expression of MMP9 mRNA]; Famotidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of MMP9 protein] |
CTD |
PMID:17603938 PMID:22257724 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases expression |
ISO EXP |
Famotidine inhibits the reaction [Acids results in increased activity of MPO protein] Famotidine results in increased expression of MPO protein Famotidine inhibits the reaction [Ethanol results in increased activity of MPO protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]; Famotidine promotes the reaction [Chlorpheniramine results in decreased activity of MPO protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]] |
CTD |
PMID:12023551 PMID:16091555 PMID:16437673 PMID:17603938 PMID:18726076 PMID:19034656 PMID:19497431 PMID:20723003 PMID:22257724 PMID:25926722 PMID:27474069 More...
|
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Indomethacin results in increased expression of MYD88 protein] |
CTD |
PMID:38447874 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Indomethacin results in increased expression of NFKB1 protein] |
CTD |
PMID:38447874 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Indomethacin results in increased expression of NFKB2 mRNA] |
CTD |
PMID:38447874 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Famotidine results in decreased expression of NPPB protein |
CTD |
PMID:30310171 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
[Pyrilamine co-treated with Famotidine co-treated with ciproxifan] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; [Pyrilamine co-treated with Famotidine] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; Famotidine inhibits the reaction [Histamine results in increased expression of NTF3 protein] |
CTD |
PMID:21276809 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Famotidine co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Famotidine promotes the reaction [Acetic Acid results in increased expression of PCNA protein] |
CTD |
PMID:18853145 PMID:19251492 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression |
EXP |
Famotidine results in decreased expression of PPP3CA protein |
CTD |
PMID:30310171 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prdx3 |
peroxiredoxin 3 |
increases expression |
EXP |
Famotidine results in increased expression of PRDX3 protein |
CTD |
PMID:30310171 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Famotidine results in increased expression of PRL protein |
CTD |
PMID:8104296 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in increased expression of PTGS1 mRNA] |
CTD |
PMID:27645307 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Famotidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA] Famotidine inhibits the reaction [Indomethacin results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:27645307 PMID:38447874 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of RELA protein] |
CTD |
PMID:27474069 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Famotidine affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
affects expression |
ISO |
Famotidine affects the expression of HLA-DMB mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
Heparin promotes the reaction [[Famotidine co-treated with Lipopolysaccharides] results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc19a3 |
solute carrier family 19 member 3 |
multiple interactions increases uptake |
ISO |
Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] SLC19A3 protein results in increased uptake of Famotidine |
CTD |
PMID:26528626 |
|
NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases uptake affects transport |
ISO EXP |
Famotidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein results in increased uptake of Famotidine SLC22A1 protein affects the transport of Famotidine |
CTD |
PMID:16006492 PMID:16141367 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake multiple interactions |
ISO EXP |
SLC22A2 protein results in increased uptake of Famotidine Famotidine inhibits the reaction [SLC22A2 protein affects the transport of Tetraethylammonium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:15496291 PMID:16006492 PMID:16141367 PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions decreases activity |
ISO |
Famotidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Famotidine results in decreased activity of SLC22A3 protein |
CTD |
PMID:16141367 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake |
ISO EXP |
estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Famotidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:15100168 PMID:15319347 PMID:15496291 PMID:16006492 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Acids affects the localization of TACR1 protein] |
CTD |
PMID:16091555 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Indomethacin results in increased expression of TLR4 protein] |
CTD |
PMID:38447874 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO EXP |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Famotidine results in increased secretion of TNF protein Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]] Famotidine inhibits the reaction [Ethanol results in increased expression of TNF protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of TNF protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of TNF mRNA] |
CTD |
PMID:11752121 PMID:12538815 PMID:17603938 PMID:17698507 PMID:19277450 PMID:27474069 PMID:27645307 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb9 |
ATP binding cassette subfamily B member 9 |
decreases expression |
EXP |
Fluconazole results in decreased expression of ABCB9 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr12:32,499,213...32,531,932
Ensembl chr12:32,499,225...32,531,931
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
EXP |
Fluconazole results in decreased expression of ADH1 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases expression |
EXP |
Fluconazole results in increased expression of AKR7A3 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression |
EXP |
Fluconazole results in decreased expression of APOA4 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
EXP |
Fluconazole results in increased expression of CES2 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
affects activity |
ISO |
Fluconazole affects the activity of CYP17A1 protein |
CTD |
PMID:31330226 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
[Fluconazole results in decreased activity of CYP19A1 protein] which results in decreased chemical synthesis of Estrone; [Fluconazole results in decreased activity of CYP19A1 protein] which results in decreased metabolism of Androstenedione |
CTD |
PMID:31330226 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
Fluconazole results in increased expression of CYP1A2 mRNA |
CTD |
PMID:16730040 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
Fluconazole results in increased expression of CYP26A1 mRNA |
CTD |
PMID:19429397 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
increases expression |
ISO |
Fluconazole results in increased expression of CYP26B1 mRNA |
CTD |
PMID:19429397 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
NR1I3 promotes the reaction [Fluconazole results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:16730040 PMID:25656644 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
EXP |
Fluconazole results in decreased expression of CYP2C mRNA |
CTD |
PMID:16643972 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
Fluconazole results in increased expression of CYP2C55 mRNA |
CTD |
PMID:16730040 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity increases expression multiple interactions increases metabolic processing |
ISO |
Fluconazole results in decreased activity of CYP2C19 protein Fluconazole results in increased expression of CYP2C29 mRNA [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole CYP2C19 protein results in increased metabolism of Fluconazole |
CTD |
PMID:12464242 PMID:15843491 PMID:16730040 PMID:17702393 PMID:19328226 PMID:26599973 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2g1 |
cytochrome P450, family 2, subfamily g, polypeptide 1 |
decreases expression |
EXP |
Fluconazole results in decreased expression of CYP2G1 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr 1:82,145,635...82,156,862
Ensembl chr 1:82,145,073...82,156,828
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
ISO |
Fluconazole results in decreased expression of CYP2J9 mRNA |
CTD |
PMID:16730040 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Fluconazole results in decreased activity of CYP3A4 protein |
CTD |
PMID:15784650 PMID:15843491 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression affects expression |
EXP |
Fluconazole results in increased expression of CYP3A23-3A1 mRNA Fluconazole affects the expression of CYP3A23-3A1 mRNA |
CTD |
PMID:16643972 PMID:20623750 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
Fluconazole results in increased expression of CYP3A13 mRNA |
CTD |
PMID:16643972 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity decreases response to substance multiple interactions |
ISO |
Fluconazole results in decreased activity of CYP51A1 protein CYP51A1 gene results in decreased susceptibility to Fluconazole CYP51A1 gene inhibits the reaction [Fluconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Fluconazole results in decreased metabolism of and results in increased abundance of 14-methylergosta-8,24(28)-dien-3,6-diol]; CYP51A1 gene inhibits the reaction [Fluconazole results in decreased metabolism of and results in increased abundance of Lanosterol] |
CTD |
PMID:16989930 PMID:18694951 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Fluconazole results in increased expression of GSTM1 mRNA |
CTD |
PMID:16730040 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Fluconazole results in decreased expression of JUND mRNA |
CTD |
PMID:16643972 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
EXP |
Fluconazole results in increased expression of LCN2 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Mark2 |
microtubule affinity regulating kinase 2 |
increases expression |
ISO |
Fluconazole results in increased expression of MARK2 mRNA |
CTD |
PMID:16730040 |
|
NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652
| |